Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0616 open-label extension in adults with hypercholesterolemia
2023-504922-20-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 28
01
Overview
Phase 3, open-label, single-arm trial of enlicitide in hypercholesterolemia, sponsored by Merck & Co. Primary endpoints: Number of participants with one or more adverse events and Number of participants who discontinue study drug due to an adverse event. Planned start Aug 2024; status: authorised.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2023-504922-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504922-20-00.